<DOC>
	<DOCNO>NCT00777686</DOCNO>
	<brief_summary>The goal clinical research study learn magnetic resonance image magnetic resonance spectroscopy ( `` MRI/MRS '' scan ) measure extra growth tumor show regular MRI image . This study procedure perform patient recurrent glioblastoma either treat chemotherapy block blood vessel growth , soon begin type chemotherapy .</brief_summary>
	<brief_title>Measuring Non-Enhancing Glioblastoma Progression</brief_title>
	<detailed_description>The Study Procedures : MRI scan commonly use check status glioblastoma . In study , MRI scan also use try good understand chemotherapy block blood vessel growth may affect status glioblastoma . The timing MRI scan study do schedule routine patient care . There extra MRI scan perform , MRS portion MRI scan add . The MRS result use study look chemical difference cancerous normal tissue , order try good understand chemotherapy may work . Screening Tests : Before begin study , `` screening test '' help doctor decide eligible take part study . The following test procedure perform : - Blood ( 1 teaspoon ) drawn routine test . - Women able child must negative blood ( 1 teaspoon ) pregnancy test . MRI/MRS Scanning : If find eligible take part study , MRI/MRS scan brain . The first scan perform chemotherapy start ( either first cycle type chemotherapy next cycle , depend whether receive type chemotherapy study ) . After , MRI/MRS scan repeat Weeks 8 16 begin chemotherapy . The MRI/MRS scan follow procedure use MRI scanner machine regular MRI scan , take additional 10 minute . You lie still back head place within opening scanner . A contrast solution , help make tumor visible , give needle vein . The scanning procedure take hour visit . The result MRI/MRS scan use affect course treatment . Tissue Collection : If regular doctor recommend tumor surgically remove , surgery discuss detail sign separate inform consent form . Leftover tissue remove surgery collect use part study . The tissue use check status disease , compare MRI/MRS image . Biomarker Testing : In study , also blood drawn biomarker test . Biomarkers chemical `` marker '' blood , body fluid , tissue may relate status disease and/or effect treatment . This blood ( 2 teaspoon time ) drawn chemotherapy start every 8 week study . The blood draw occur day MRI/MRS scan . Length Study Participation : You continue blood drawn biomarker test every 8 week , unless stop taking type chemotherapy block blood vessel growth . In case , take study . If surgery , participation study end surgery . If unable surgery , participation end last MRI/MRS scan . This investigational study . MRI scan FDA approve commercially available procedure check status glioblastoma . At time purpose , MRS scan use research . Up 18 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>1 . Patients histologically prove intracranial glioblastoma gliosarcoma eligible protocol 2 . Patients recurrent glioblastoma gliosarcoma schedule start systemic chemotherapy bevacizumab . 3 . Patients tumor must locate area amenable propose imaging sequence . 4 . Patients must age 18 old . 5 . Karnofsky Performance Status Scale ( KPS ) &gt; /= 70 . 6 . Inclusion Women Minorities : Both men woman member race ethnic group eligible trial . 7 . Patients must sign informed consent indicate aware investigational nature study keep policy hospital . The acceptable consent form one attached end protocol . 1 . Patients histologically prove intracranial glioblastoma gliosarcoma eligible protocol 2 . Patients recurrent glioblastoma gliosarcoma schedule start systemic chemotherapy bevacizumab . 3 . Patients tumor must locate area amenable propose imaging sequence . 4 . Patients must age 18 old . 5 . KPS &gt; /= 70 . 6 . Inclusion Women Minorities : Both men woman member race ethnic group eligible trial . 7 . Patients must sign informed consent indicate aware investigational nature study keep policy hospital .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Intracranial Glioblastoma</keyword>
	<keyword>Intracranial Gliosarcoma</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>recurrent glioblastoma</keyword>
	<keyword>gliosarcoma</keyword>
	<keyword>brain cancer</keyword>
	<keyword>magnetic resonance spectroscopy</keyword>
	<keyword>MRS</keyword>
	<keyword>magnetic resonance imaging</keyword>
	<keyword>MRI</keyword>
	<keyword>MRI/MRS</keyword>
	<keyword>Recurrent Glioblastoma Treated Antiangiogenic agent</keyword>
	<keyword>contrast enhance MRI</keyword>
	<keyword>DCE-MRI</keyword>
	<keyword>diffusion-weighted MRI</keyword>
	<keyword>DSC</keyword>
	<keyword>DW-MRI</keyword>
</DOC>